重组干扰素α-2在胃肠道癌中的体外II期试验
In vitro phase II trial of recombinant interferon alpha-2 in gastrointestinal cancer.
作者信息
Scheithauer W, Temsch E M, Schieder K, Funovics H, Schiessel R, Grabner G
出版信息
Int J Cell Cloning. 1985 Jul;3(4):188-98. doi: 10.1002/stem.5530030401.
The antitumor effects of recombinant interferon alpha-2 (rIF) on clonogenic tumor cells were investigated in 29 cases of gastrointestinal cancer. An in vitro response (greater than or equal to 50% inhibition of tumor colony-forming units) was observed in 17% of the tumors, including 2 of 8 pancreatic, 2 of 6 gastric, and 1 of 10 colon cancer specimens. The relative efficacy of rIF in tissue cultures of pancreatic and gastric tumors was further substantiated by the resistance against simultaneously tested single conventional cytostatic drugs. Preliminary results of comparative studies of cloned interferon alpha-2 and human purified leukocyte interferon (hlIF) in 2 human colon cancer cell lines and 11 fresh tumor specimens suggest similar trends in terms of colony inhibition in individual assays. However, the interpatient differences indicate an overall superiority of the natural preparation (P less than 0.02).
在29例胃肠道癌患者中研究了重组干扰素α-2（rIF）对克隆性肿瘤细胞的抗肿瘤作用。在17%的肿瘤中观察到体外反应（肿瘤集落形成单位抑制率大于或等于50%），包括8例胰腺癌标本中的2例、6例胃癌标本中的2例和10例结肠癌标本中的1例。通过对同时检测的单一传统细胞毒性药物的耐药性，进一步证实了rIF在胰腺和胃肿瘤组织培养中的相对疗效。对2个人结肠癌细胞系和11个新鲜肿瘤标本进行克隆干扰素α-2和人纯化白细胞干扰素（hlIF）比较研究的初步结果表明，在个体试验中，两者在集落抑制方面有相似趋势。然而，患者间差异表明天然制剂总体上更具优势（P<0.02）。
Zotero 插件